Results 281 to 290 of about 406,491 (336)
BHLHE40 Is a Transcriptional Regulatory Target of NFE2L3 in Triple-Negative Breast Cancer. [PDF]
Oncol ResModi SR, Andey T, Acquaah-Mensah G.
europepmc +1 more source
A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates
Advanced Science, EarlyView.Membrane proteins remain challenging targets for conventional TPD approaches. Here, the authors develop UPTAB, a modular platform leveraging ultrahigh‐affinity orthogonal Im/CL protein pairs for lysosomal degradation of membrane proteins. Mono‐targeted (Type‐I), dual‐targeted (Type‐II), and tri‐targeted (Type‐III) UPTABs enable simultaneous degradation
Mengqing Zhao +7 more
wiley +1 more source
Decoding the Clinical and Therapeutic Significance of MEAK7 in Triple-Negative Breast Cancer Through Integrative Bioinformatics. [PDF]
Biology (Basel)Ayan D, Kan MU, Bayram E, Soylemez S.
europepmc +1 more source
Editorial: Deciphering cell-cell interactions in triple-negative breast cancer. [PDF]
Front ImmunolYang X, Zhu L, Li X, Du Y.
europepmc +1 more source
Assessing the prognostic role of androgen receptor expression in non-metastatic triple-negative breast cancer. [PDF]
Front OncolAl-Masri M +8 more
europepmc +1 more source
HDHD5 promotes triple-negative breast cancer growth and drives EMT-associated phenotypes via regulating S100A4. [PDF]
J Cancer Res Clin OncolCai JY +5 more
europepmc +1 more source
Therapeutic synergies that overcome carboplatin resistance in triple-negative breast cancer. [PDF]
J Exp Clin Cancer ResAltman JE +8 more
europepmc +1 more source
Polish journal of pathology : official journal of the Polish Society of Pathologists, 2015 Janusz, Ryś, Anna, Kruczak
openaire +1 more source